NASDAQ / LIVE COMPANY INTELLIGENCE

Quantum Biopharma Ltd.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERQNTM
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / QNTM COVERAGE

What’s moving Quantum Biopharma Ltd. now

Current reporting with the operating signal separated from the noise.

01
TradingView

Quantum Biopharma Ltd expected to post a loss of 42 cents a share - Earnings Preview

Investors are testing whether Quantum Biopharma Ltd.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Quiver Quantitative

Quantum BioPharma Ltd. Closes CAD$123,487.43 Debt Settlement Through Share Issuance

Investors are testing whether Quantum Biopharma Ltd.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
TradingKey

Quantum BioPharma Ltd (QNTM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Investors are testing whether Quantum Biopharma Ltd.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Missionirnewsbreaks Quantum Biopharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development Of Neuroprotective Therapy

Missionirnewsbreaks Quantum Biopharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development Of Neuroprotective Therapy

The story matters when it changes Quantum Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Class B (Sub Voting)

Quantum BioPharma Ltd. - Ordinary Shares

Investors are testing whether Quantum Biopharma Ltd.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

The story matters when it changes Quantum Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
Quantum BioPharma Ltd. Announces Positive Results from Clinical Trial of unbuzzd™ Dietary Supplement for Alcohol Intoxication Relief

Quantum BioPharma Ltd. Announces Positive Results from Clinical Trial of unbuzzd™ Dietary Supplement for Alcohol Intoxication Relief

The story matters when it changes Quantum Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
08
Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM

Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM

The story matters when it changes Quantum Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest QNTM filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

6-KOfficial SEC filingFiled 2026-06-02 · Period 2026-06-02SEC ↗6-KOfficial SEC filingFiled 2026-06-02 · Period 2026-06-02SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-08SEC ↗6-KOfficial SEC filingFiled 2026-05-18 · Period 2026-05-18SEC ↗6-KOfficial SEC filingFiled 2026-05-07 · Period 2026-05-07SEC ↗6-KOfficial SEC filingFiled 2026-05-06 · Period 2026-03-31SEC ↗6-KOfficial SEC filingFiled 2026-04-22 · Period 2026-04-22SEC ↗6-KOfficial SEC filingFiled 2026-04-02 · Period 2026-04-02SEC ↗
EARNINGS / QUARTERLY TRACKER

Quantum Biopharma Ltd., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.